SG&A Efficiency Analysis: Comparing Dr. Reddy's Laboratories Limited and TG Therapeutics, Inc.

SG&A Efficiency: Dr. Reddy's vs. TG Therapeutics

__timestampDr. Reddy's Laboratories LimitedTG Therapeutics, Inc.
Wednesday, January 1, 20143878300000024518692
Thursday, January 1, 20154258500000019886580
Friday, January 1, 20164570200000012631689
Sunday, January 1, 20174637200000021977998
Monday, January 1, 20184691000000020759000
Tuesday, January 1, 20194889000000020838000
Wednesday, January 1, 202050129000000121812000
Friday, January 1, 202154559000000152137000
Saturday, January 1, 20226208100000083231000
Sunday, January 1, 2023105931000000122706000
Monday, January 1, 202477201000000
Loading chart...

In pursuit of knowledge

SG&A Efficiency: A Tale of Two Companies

In the competitive landscape of pharmaceuticals, understanding the efficiency of Selling, General, and Administrative (SG&A) expenses is crucial. Dr. Reddy's Laboratories Limited and TG Therapeutics, Inc. offer a fascinating contrast in this regard. Over the past decade, Dr. Reddy's has consistently increased its SG&A expenses, peaking at a staggering 106% increase from 2014 to 2023. This reflects their aggressive expansion and market penetration strategies. In contrast, TG Therapeutics, Inc. has shown a more volatile pattern, with a notable spike in 2021, where expenses surged by over 500% compared to 2014, indicating significant investment in growth and development. However, data for 2024 is missing, leaving room for speculation on future trends. This analysis highlights the strategic differences between a well-established giant and a burgeoning innovator in the pharmaceutical industry.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025